Provectus Biopharmaceuticals, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2003 | -30.8% | -30.8% | — |
| FY2004 | -47.4% | -47.4% | — |
| FY2005 | -81.8% | -81.8% | — |
| FY2006 | -57.1% | -57.1% | — |
| FY2007 | -67.5% | -67.5% | — |
| FY2008 | -102.1% | -102.1% | — |
| FY2009 | -131.0% | -131.0% | — |
| FY2010 | -173.4% | -173.4% | -128.8% |
| FY2011 | -194.0% | -194.0% | -145.6% |
| FY2012 | -286.1% | -286.1% | -202.6% |
| FY2013 | -417.8% | -417.8% | -138.4% |
| FY2014 | -40.7% | -40.7% | -39.1% |
| FY2015 | -150.2% | -150.2% | -119.9% |
| FY2016 | -704.1% | -704.1% | -435.3% |
| FY2017 | 134.9% | 134.9% | -393.4% |
| FY2018 | 46.8% | 46.8% | -410.1% |
| FY2019 | 28.8% | 28.8% | -468.7% |
| FY2020 | 22.1% | 22.1% | -1,133.3% |
| FY2021 | 132.3% | 132.3% | -157.7% |
| FY2022 | 57.1% | 57.1% | -174.5% |
| FY2023 | 40.8% | 40.8% | -214.1% |
| FY2024 | 79.4% | 79.4% | -470.3% |
| FY2025 | 86.2% | 86.2% | -778.6% |